Akebia Therapeutics, Inc. (AKBA) — Financial statements
Income statement, balance sheet, and cash flow for Akebia Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 236↑47.5% | 160↓17.7% | 195↓33.5% | 292↑38.2% | 212 | |
| Cost of Revenue | 39↓37.5% | 63↓14.8% | 74↑229.6% | 22↓72.4% | 81 | |
| Gross Profit | 197↑102.8% | 97↓19.5% | 120↓55.4% | 270↑107.4% | 130 | |
| Operating Expenses | ||||||
| R&D Expenses | 62↑65.6% | 38↓40.3% | 63↓62.0% | 166↑12.3% | 148 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00↓100.0% | 132↓20.5% | 166 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 100↑1396.0% | 7↓18.3% | 8 | |
| SG&A Expenses | 107↑0.9% | 107↑6.3% | 100↓27.7% | 139↓20.4% | 174 | |
| Other Expenses | 3↑3.6% | 3↓4.1% | 3↓92.6% | 46↓36.4% | 73 | |
| Operating Expenses | 173↑17.5% | 147↓11.5% | 167↓52.5% | 351↓11.1% | 395 | |
| Total Costs & Expenses | 213↑1.0% | 211↓12.5% | 241↓35.5% | 373↓21.6% | 476 | |
| Operating Results | ||||||
| Operating Income | 23↑146.6% | -50↓9.1% | -46↑42.7% | -81↑69.5% | -265 | |
| Depreciation & Amortization | 1↓96.6% | 38↓0.3% | 38↓0.2% | 38↓0.7% | 38 | |
| EBITDA | 22↑258.3% | -14↓66.0% | -8↓370.5% | 3↑101.6% | -190 | |
| EBIT | 20↑139.9% | -51↓11.6% | -46↓32.5% | -35↑84.8% | -228 | |
| Interest & Other Income | ||||||
| Net Interest Income | -24↓33.0% | -18↓201.5% | -6↑61.5% | -16↑21.3% | -20 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 24↑33.0% | 18↑201.5% | 6↓61.5% | 16↓21.3% | 20 | |
| Non-Operating Income | 3↑303.9% | 0.75↑307.4% | -0.36↑99.2% | -46↓26.0% | -37 | |
| Other Income / Expenses | -27↓43.7% | -19↓234.1% | -6↑57.8% | -13↑23.3% | -18 | |
| Income Before Tax | -4↑94.6% | -69↓33.7% | -52↑44.9% | -94↑66.6% | -282 | |
| Income Tax Expense | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -5↑92.3% | -69↓33.7% | -52↑44.9% | -94↑66.6% | -282 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -5↑92.3% | -69↓33.7% | -52↑44.9% | -94↑66.6% | -282 | |
| Bottom-Line Net Income | -5↑92.3% | -69↓33.7% | -52↑44.9% | -94↑66.6% | -282 | |
| EPS (Basic) | -0.02↑93.7% | -0.33↓17.9% | -0.28↑51.7% | -0.58↑60.8% | -1.48 | |
| EPS (Diluted) | -0.02↑93.7% | -0.33↓17.9% | -0.28↑51.7% | -0.58↑60.8% | -1.48 | |
| Weighted Average Shares | 257↑21.9% | 211↑12.5% | 187↑2.6% | 183↑10.1% | 166 | |
| Weighted Average Diluted Shares | 257↑21.9% | 211↑12.5% | 187↑2.6% | 183↑10.1% | 166 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.